U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06866665) titled 'Antithrombotic Strategy for AF Patients With High Risk CAD' on Feb. 23.
Brief Summary: Anticoagulation therapy is recommended for patients with atrial fibrillation (AF) in order to prevent ischemic stroke and systemic embolism. Meanwhile, lifelong antiplatelet therapy is highly recommended to prevent stent thrombosis and further ischemic adverse events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation. In this context, in patients with AF undergoing DES implantation, anticoagulation and antiplatelet therapies perform their own unique roles. However, the current guidelines recommend to discont...